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ABSTRACT
Objective: The objective of this study is to analyze the cortisol levels in induction and alternate phases associated with the clinical manifestation in 
the developing of adrenal suppression.
Methods: An observational, longitudinal study which had been approved by the ethical committee of Dr. Soetomo Teaching Hospital Surabaya was 
conducted from June to October 2016. The cortisol levels were measured before induction phase (t=0), after induction phase (t=1), and after alternate 
phase (t=2). The venous blood samples were obtained in the morning at 08.00–09.00 am. The data were analyzed using student’s t-test.
Results: A total of 15 patients were included, but 6 patients were excluded because of cross-reactivity with prednisone when using ADVIA Centaur Cortisol 
Assay. 9 patients (55.56% boys) had a mean age 6–< 12 years old and 33.33% were initial attack and dependent steroid nephrotic syndrome. 8 of 9 patients 
had a normal cortisol level at baseline (t=0). The cortisol level decrement in the induction phase was 72.92% (11.79±10.66 mcg/dL–1.75±1.08 mcg/dL) 
(*p=0.024). After alternate phase, the cortisol levels increased 417.60% (1.75±1.08 mcg/dL to 5.95±3.33 mcg/dL (*p=0.007). The clinical manifestation as 
nausea/vomiting and abdominal distension only appeared in 11.11% of patients in the induction phase but not in the alternate phase.
Conclusions: Hypothalamus-pituitary-adrenal (HPA) axis suppression could develop after induction phase which was indicated by low cortisol levels. 
High-dose and long-term prednisone exposure decreased the cortisol levels reversibly. The clinical manifestation of adrenal suppression as weakness, 
nausea/vomiting, acute dehydration, and abdominal distension almost did not manifest in all patients.
Keywords: Cortisol, Nephrotic syndrome, Sensitive steroid nephrotic syndrome, Prednisone, High-dose prednisone, Long-term prednisone, 
Hypothalamus-pituitary-adrenal axis suppression, Children.
INTRODUCTION
Nephrotic syndrome (NS) is a glomerular disease characterized by heavy 
protein urine (≥40 mg/m2/h or more than 50 mg/kg/day or dipstick 
≥2+), hypoalbuminemia (≤2.5 g/dL), and edema and may accompanied 
by hypercholesterolemia (>200 mg/dL) [1-5]. The incidence of this 
disease in America and Europe was occurred in 1–3/100,000 in children 
with the mean age of <16 years old. The cumulative incidence was 
16/100,000 with the ratio between boy and girl 3.8:1 [5,6]. In Indonesia, 
the prevalence of this disease was 6 cases per 100,000 children each 
year with the ratio between boy and girl 2:1 [1,4].
The regimen therapy of NS was prednisone of 60 mg/m2 or 2 mg/kg/day 
for 4 weeks or until remission (relapse) for 3–4 weeks followed by the 
alternate-day prednisone of 40 mg/m2 or 1.5 mg/kg/day for 4–12 weeks. 
There was a difference among guidelines for the duration of prednisone 
therapy, some guidelines recommended longer prednisone therapy for 
3–6 months including full dose, and alternating dose could decrease 
risk relapse than therapy for 2–3 months [4,5,7]. The main effect of 
high-dose and long-term prednisone was hypothalamus-pituitary-
adrenal (HPA) axis suppression. It could suppress endogenous cortisol 
production through suppression adrenal cortex [8,9].
The mechanism of HPA axis suppression was occurred by short- and 
long-loop feedback in corticotropin-releasing hormone (CRH) neuron. 
The suppression of CRH neuron decreased the production of CRH 
mRNA, CRH, and ACTH. The net result of HPA axis suppression was 
decreasing cortisol production level in the adrenal cortex, especially in 
fasciculate zone [10,11]. The adrenal cortex suppression caused acute 
and chronic adrenal insufficiency which indicated by acute dehydration, 
hypotension, hypoglycemia, altered mental status, fatigue/weakness, 
anorexia, nausea, vomiting, loss of appetite, weight loss, and abdominal 
pain [12-14]. The children with NS who exposure to prednisone 
could develop adrenal suppression. The recovery period of it was not 
completely determined, but it could last up to 1 year [15].
Study-related HPA axis suppression was conducted since 1965 
by measuring cortisol level after giving synacthen test. The result 
showed HPA axis suppression which indicated by decrease cortisol 
level [16-18]. The current study conducted in children with NS showed 
that there were possibilities in developing HPA axis suppression 
which was indicated by decrease cortisol level and increasing risk 
relapse [19]. Another study with different regimens conducted in adult 
showed the same result as in children [20]. However, how far the effect 
of prednisone therapy in children with sensitive NS in Dr. Soetomo 
Teaching Hospital Surabaya has not been determined. Therefore, 
to monitor cortisol level during high dose and long term prednisone 
therapy in nephrotic syndrome is necessary.
METHODS
We conducted a prospective, observational, and longitudinal study 
from June to October 2016 at the Pediatric Nephrology Department of 
Dr. Soetomo Teaching Hospital Surabaya. We recruited 16 children who 
diagnosed as steroid-sensitive NS, aged <18 years old, and followed 
this study until finish. We excluded patients who diagnosed as steroid-
resistant NS and took prednisone <24 h. We dropped outpatient who 
changed diagnose during study, did not followed the study completely, 
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and died. Patients received full-dose prednisone of 2 mg/kg/day or 
60 mg/m2/day for ±4 weeks and followed by alternate-day prednisone 
of 1.5 mg/kg/day or 40 mg/m2 for ±4 weeks. The cortisol level measured 
before induction phase, after induction phase, and after alternating 
phase at 08.00–09.00 a.m.
This study had been approved by the ethical committee of Dr. Soetomo 
Teaching Hospital Surabaya. We had explained everything about this 
study in detail before starting. All data were collected from patient 
medication report and direct interview with patients. ADVIA Centaur 
Cortisol Assay was used to determine cortisol level.
Normality test performed in interval scale data using One-sample 
Kolmogorov–Smirnov. Student’s t-test was used to compare the 
cortisol level in the induction phase and alternating phase. Statistical 
analysis was performed using the computer program package 
Table 1: Baseline characteristics of nephrotic syndrome patients
Patient characteristics Total patients n=9 (%) Mean±SD
Gender
Boys 5 (55.56) -
Girls 4 (44.44) -
Age (Years)
<2 0 (0) -
2–<6 4 44.44) 3.50±1.29
6–<12 tahun 5 (55.56) 7.80±1.92
12–18 tahun 0 (20) -
Body weight
0–20.9 kg 7 (77.78) 16.47±3.38
21–40.9 kg 1 (11.11) 21.00 
41–60 kg 1 (11.11) 50.00
Blood pressure
Normal (90–135/55–85 mmHg) 9 (100) 98.33/6667±10.61/12.25
Hypertension (>135/>85 mmHg) 0 (0) -
Blood glucose
<2 years (60–100 mg/dL) 0 (0) 0
>2 years–adult (<200 mg/dL) 9 (100) 98.44±19.37
Diagnose
Initial attack (NS) 3 (33.33) -
Infrequent relapses (NS) 2 (2.22) -
Frequent relapses (NS) 1 (11.11) -
Dependent steroid (NS) 3 (33.33) -
Cortisol level t=0
<3 mcg/dL 1 (11.11) 2.79
3–<10.164 mcg/dL 4 (44.44) 5.91±2.49
10.164–21 mcg/dL 3 (33.33) 14.25±3.43
>21 mcg/dL 1 (11.11) 36.89
Cumulative dose of prednisone 1 year 
prior t=0
Not taking prednisone 3 (33.33 0±0
1–5.000 mg 3 (33.33) 3.835.0±967.97
5.001–10.000 mg 3 (33.33) 5.888.3±618.92
>10.000 mg 0 (0) -
Duration of prednisone 1 year prior t=0
Not taking prednisone 3 (33.33) 0±0
1–225 days 5 (55.56) 183.40±33.25
226–450 days 1 (11.11) 229
>450 days 0 (0) 0±0
Edema
Without edema 1 (11.11) -
Palpebrae 2 (22.22) -
Extremity 1 (11.11) -
Anasarca 5 (55.56) -
Meal frequency (x/day)
2 0 (-) -
3 7 (77.78) -
4 1 (11.11) -
5 1 (11.11) -
Acute dehydration
Yes 0 (0) -
No 9 (100) -
Weakness/fatigue
Yes 3 (33.33) -
No 6 (66.67) -
Nausea/vomiting
Yes 2 (22.22) -
No 7 (77.78) -
Abdominal pain
Yes 4 (44.44) -
No 5 (55.56) -
NS: Nephrotic syndrome
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SPSS (version 20.0). Nominal data scale presented as a frequency 
distribution.
Overview of this cohort study was shown in Fig. 1.
RESULTS
The boy had higher percentage (55.56%) than girl with the mean age 
of 6–<12 years old (55.56%). The mean weight was 16.47±3.38 kg. 






t=0 t=1 t=2 ∆t=1‑t=0 ∆t=2‑t=1
AM (G/3 y) 3–21 10.41 1.6 3.12 −8.81 1.52
DI (G/8y) 3–21 6.15 0.62 4.92 −5.53 4.3
KY (B/2y) 3–21 15.36 2.51 1.18 −12.85 −1.33
JA (G/7y) 3–21 9.35 2.67 4.22 −6.68 1.55
MA (B/7y) 3–21 16.99 0.99 8.56 −16 7.57
AP (B/11y) 3–21 4.23 3.9 10.88 −0.33 6.98
ND (B/4y) 3–21 3.92 0.62 9.83 −3.3 9.21
RA (B/6y) 3–21 36.89 1.32 3.5 −35.57 2.18
DA (G/5y) 3–21 2.79 1.56 7.34 −1.23 5.78
Mean±SD 11.79±10.66 1.75±1.08 5.95±3.33 −10.03±10.87 4.19±3.46
SD: Standard deviation
Table 3: Clinical and laboratory manifestation of adrenal suppression
Patients’ code AM DI KY JA MA AP ND RA DA Mean±SD
Blood glucose 96 99 126 107 63 87 102 122 84 98.44±19.37
111 107 102 99 122 110 92 123 89 106.1±11.92
117 117 112 103 109 113 123 112 128 114.89±7.44
Blood pressure 90/60 90/60 95/50 100/70 110/80 120/90 90/60 90/60 100/70 98.33±10.61
66.67±12.25
90/60 90/60 100/60 90/60 100/70 120/70 90/60 90/60 80/50 94.44±11,30
61.11±6.01
90/60 100/70 90/50 90/60 100/70 110/80 100/60 90/60 90/60 95.56±7.26
63.33±8.66
Body weight 12 20 12 18 20 50 16 17 21 20.70±11.47
11 21 14 20 21 48 16 15 21 20.56±10.93
11 24 14 20 21 49 16 15 22 21.22±11.24
Meal frequency 3 3 3 3 4 3 3 5 3 3.13±0.64
6 6 5 5 7 4 6 6 5 5.4±0.74
6 5 3 3 5 3 6 5 5 4.3±1.16
16 nephrotic syndrome patients
Eligible patients for study (n=15)
Collecting venous blood samples at 08:00-09:00 a.m and data




Collecting venous blood samples at 08:00-09:00 a.m and data
t=1
Starting on day 21
Prednison 1.5 mg/kg/day
Collecting venous blood samples at 08:00-09:00 a.m and data
t=2
Starting on day 47
Cortisol level was measured by ADVIA Centaur Cortisol Assay
Statistic analysis
6 excluded patients
Fig. 1: Study flow chart
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Based on diagnosis of patient, both initial attack and dependent 
steroid NS had the same percentage (33.33%). History of duration 
and cumulative dose were determined as HPA axis suppression could 
last up to 1 year and relapse of infrequent relapse NS was <4 relapses 
in 1 year [4,15]. Baseline characteristics of all patients are showed 
in Table 1.
The majority cortisol level at t=0 was normal (44.44%), except one 
patient had cortisol subnormal (<3 mcg/dL) and one patient had the 
cortisol level higher than normal range (>21 mcg/dL). The cortisol 
level decreased into subnormal at t=1 and increased at the end of the 
alternating phase (t=2). However, AP still had normal cortisol level at 
t=1. Table 2 shows the cortisol level of NS patients.
Statistical analysis of normality showed that all data were normally 
distributed. The duration and cumulative dose of prednisone a year 
before the study showed no correlation with the cortisol level at t=0. 
Student’s t-test to compare the cortisol level at t=0 and t=1 and t=1 
and t=2 showed that there was a significant difference with*p=0.024 
and *p=0.007, respectively. Student’s t-test also used to compare the 
delta cortisol level during each phase. The results showed significant 
difference between the delta cortisol level at the end of t=1 and at the 
end of t=2 (*p=0.003).
Clinical and laboratory finding associated with HPA axis suppression 
almost did not find in patients as shown in Table 3 and Fig. 2.
DISCUSSION
A total of 15 eligible patients were recruited in this study. The diagnosis 
of one patient was changed to be lupus nephritis. Cross-reactivity was 
occurred in 6 patients when measured by ADVIA Centaur Cortisol Assay. 
It was caused by similarity structure between cortisol and prednisone 
[21].
The mean cortisol level at t=0 in some patients was lower than others. 
It was occurred because of genetic variation in HPA axis and receptor 
variation. Another variation could find in some points of HPA axis 
system such as at CRH or ACTH synthesis [22]. The history duration and 
cumulative dose of prednisone were analyzed using Pearson correlation. 
It showed no significant correlation between the history duration and 
cumulative dose of prednisone and the cortisol level at t=0 (*p>0.05). 
It was occurred because some patients were in alternating phase. 
Therefore, their cortisol level reached to the normal range [10,22]. One 
patient had subnormal cortisol level at t=0 because she took 30 mg of 
prednisone before admission. Another patient had cortisol level higher 
than normal because he was stress (crying and anxious). Acute stress 
could induce the releasing of CRH and cortisol as the end product of 
HPA axis circuit [9,23].
The mean cortisol level at t=0 and t=2 was 11.79±10.66 mcg/dL and 
1.75 mcg/dL or decreased 72.92%. Statistical analysis of the cortisol 
level at t=0 and t=1 showed significant difference with *p=0.024. The 
suppression was occurred through negative feedback in hypothalamic 
which suppressed expression of proopiomelanocortin gene at 
hypophyse and pro-CRH gene at hypothalamic, so releasing of ACTH was 
inhibited. The deficiency of ACTH caused atrophy of the adrenal gland 
[9,24]. The decrease cortisol level at t=1 indicated adrenal suppression 
which could develop if the morning cortisol level <3 mcg/dL [13,25,26]. 
However, the cortisol level at t=2 increased up to 417.60% from 
t=1 (5.95±3.33 mcg/dL). Statistical analysis showed significant 
difference with *p=0.007. The alternating-day regimen could increase 
cortisol level to normal range or the adrenal suppression at t=1 was 
reversible. Except in patient with inisial (KY), cortisol level lower than 
at t=1 received devided dose regimen which suppressed HPA axis 
higher than single dose [9,23]. Statistical analysis also was used to 
compare the delta cortisol level at the end of induction phase and the 
end of alternate phase with *p=0.003.
The clinical manifestation such as hypoglycemia, hypotension, weight 
loss, loss of appetite, and acute dehydration was not found in the 
patients in this study. Nausea/vomiting and abdominal pain were only 
found in 7% after the induction phase caused by prednisone side effect 
on the digestive tract [27,28].
The limitation of this study was that some patients had cross-reaction 
with prednisone when using ADVIA Centaur Cortisol Assay. We had to 
make sure the compliance of patient not to taking prednisone before 
collecting the sample. Another limitation was that the incidence of NS 
was rare, so it was difficult to find the subject in short period.
CONCLUSIONS
HPA axis suppression was occurred in the induction phase which 
indicated by the decrease of cortisol level 72.92%. The suppression was 
reversible which was indicated by the increase of the cortisol level at 
the end of the alternating phase 417.60%. The clinical manifestation 
only such as nausea/vomiting only found in 11.11%. However, we need 
do the longer study with many patients to support the result in this 
study, and further discussion will be needed.
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